Equillium Announces the Appointment of Katherine Xu to the Board of Directors
February 09 2021 - 8:00AM
Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company
developing itolizumab to treat severe autoimmune and inflammatory
disorders, today announced that Y. Katherine Xu, Ph.D., partner at
Decheng Capital, has been appointed to Equillium’s board of
directors, effective Thursday, February 4, 2021.
“We’re excited to have Dr. Xu join the board of directors, as
she brings with her a wealth of both scientific and Wall Street
acumen,” said Dan Bradbury, executive chairman of the board of
directors at Equillium. “Her addition complements the skills and
experience of our board and her background will add a valuable
perspective as Equillium transitions to later-stage
development.”
“I’m thrilled to be joining Equillium’s board of directors at
such an important time for the company,” said Dr. Xu. “Targeting
the CD6-ALCAM pathway to treat severe autoimmune and inflammatory
diseases is highly novel and very exciting, as itolizumab recently
demonstrated compelling interim data in the first-line treatment of
acute graft-versus-host disease. With multiple data milestones on
the horizon from all three clinical programs, I look forward to
working with the rest of the board and the leadership team as we
develop strategies to bring this innovative and impactful therapy
to patients with high unmet medical needs.”
Dr. Y. Katherine Xu is a partner at Decheng Capital and has been
with the firm since May 2019. Prior to joining Decheng, Dr. Xu was
Partner, Senior Biotechnology Analyst and Co-Group Head of the
Biopharmaceutical Equity Research team at William Blair &
Company based in New York. Prior to William Blair, Dr. Xu was
Senior Vice President and Senior Biotechnology Analyst at Wedbush
Securities, Vice President and Senior Biotechnology Analyst at
Credit Suisse, and Senior Biotechnology Analyst at Pacific Growth
Equities. Before her move to equity research, Dr. Xu was Vice
President of Investment Banking at Petkevich & Partners, a
boutique investment banking firm in San Francisco focused on the
life sciences industry. Dr. Xu serves on the board of directors for
The 1990 Institute and The Overseas Young Chinese Forum, two
China-related non-profit organizations.
Dr. Xu holds a Ph.D. in developmental biology and a Ph.D. minor
in engineering-economic systems and operations research from
Stanford University Schools of Medicine and Engineering,
respectively. She attended Peking University in Beijing before
transferring to Kalamazoo College in Michigan in her junior year,
where she gained her B.A. with honors.
About EquilliumEquillium is a clinical-stage
biotechnology company leveraging deep understanding of
immunobiology to develop novel products to treat severe autoimmune
and inflammatory disorders with high unmet medical need. Equillium
is developing itolizumab for multiple severe immuno-inflammatory
diseases, including acute graft-versus-host-disease (aGVHD),
lupus/lupus nephritis and uncontrolled asthma.For more information,
visit www.equilliumbio.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to statements regarding the ability of Equillium to
transition to later-stage development, the timing of clinical trial
data readouts, Equillium’s plans and expected timing for developing
itolizumab and potential benefits of itolizumab. Risks that
contribute to the uncertain nature of the forward-looking
statements include: Equillium’s ability to execute its plans and
strategies; risks related to performing clinical trials; the
risk that interim results of a clinical trial do not necessarily
predict final results and that one or more of the clinical outcomes
may materially change as patient enrollment continues, following
more comprehensive reviews of the data, and as more patient data
become available; potential delays in the commencement, enrollment
and completion of clinical trials and the reporting of data
therefrom; the risk that studies will not
be completed as planned; Equillium’s plans and product
development, including the initiation and completion of clinical
trials and the reporting of data therefrom; whether the results
from clinical trials will validate and support the safety and
efficacy of itolizumab; and changes in the competitive landscape.
These and other risks and uncertainties are described more fully
under the caption "Risk Factors" and elsewhere in Equillium's
filings and reports with the SEC. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Equillium undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor ContactMichael Moore Vice President,
Investor Relations & Corporate
Communications+1-619-302-4431ir@equilliumbio.com
Media ContactKatherine Carlyle SmithSenior
Account AssociateCanale Communications+1-805-907-2497
katherine.smith@canalecomm.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2023 to Apr 2024